Researchers disclosed a first‑in‑class inhibitor targeting GAS41, the YEATS4‑encoded chromatin reader frequently overexpressed in non‑small‑cell lung cancer (NSCLC). Preclinical data presented indicate the compound modulates transcriptional programs linked to tumor growth and may offer a new epigenetic entry point for NSCLC therapy. GAS41/YEATS4 functions as a chromatin‑associated regulator; targeting it represents an epigenetic strategy distinct from kinase inhibitors or immune therapies. The candidate now warrants translational evaluation for select patient subgroups and combination strategies where epigenetic modulation could restore therapeutic sensitivity.